OR WAIT null SECS
August 08, 2022
Newly unveiled workplan focuses on harnessing the impact of big data on drug development—and ultimately public health.
July 26, 2022
The scope of RWE’s use in developing and approving new medicines is pitting key healthcare stakeholders against each other.
July 18, 2022
Payers join the push for better demonstrations of efficacy of new medicines.
July 01, 2022
Largely discarded topic beginning to grab hold in policy discussions.
June 23, 2022
Battle lines being drawn among key healthcare constituencies, as discussions around new approaches to drug evaluation and decision-making heat up.
June 17, 2022
The reporting of one man in Europe is changing accountability with compliance.
June 13, 2022
But despite showing a tightening of focus on clinical trials and evidence, the annual report doesn’t paint the full picture.
May 26, 2022
EMA’s new release factors in scientific advances, clarity on trial designs.
May 23, 2022
Just-released analysis by Prescrire contends that the agency “is backtracking on commitments to clinical data transparency.”
May 12, 2022
EMA continues to familiarize industry with new clinical trial legislation.